Biomarkers for acute GVHD: Can we predict the unpredictable

Bone Marrow Transplantation

Volumn 48, Issue 6, 2013, Pages 755-760

  Chen, Y B ^a   Cutler, C S ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

biomarkers; GVHD; transplant

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD30 ANTIGEN; CYTOKERATIN 18; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANZYME A; GRANZYME B; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 2; SCATTER FACTOR; SYNDECAN 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VERY LATE ACTIVATION ANTIGEN 4;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; CYTOKINE RESPONSE; DIAGNOSTIC ACCURACY; HIGH RISK POPULATION; HUMAN; LEUKOCYTE ACTIVATION; LEUKOCYTE FUNCTION; LEUKOCYTE MIGRATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

ACUTE DISEASE; ALLOGRAFTS; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; ELAFIN; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERLEUKIN-2; LECTINS, C-TYPE; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879123370     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.143     Document Type: Review

References (53)

1. Miyamoto T, Akashi K, Hayashi S, Gondo H, Murakawa M, Tanimoto K et al. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transplant 1996; 17: 185-190.
2. Grimm J, Zeller W, Zander AR. Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantations as a marker for GVHD. Bone Marrow Transplant 1998; 21: 29-32.
3. Foley R, Couban S, Walker I, Greene K, Chen CS, Messner H et al. Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogenic bone marrow transplantation. Bone Marrow Transplant 1998; 21: 769-773.
4. Mathias C, Mick R, Grupp S, Duffy K, Harris F, Laport G et al. Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft-versus-host disease after allogeneic bone marrow transplantation. J Hematother Stem Cell Res 2000; 9: 393-400.
5. Lee SJ, Zahrieh D, Agura E, MacMillan ML, Maziarz RT, McCarthy Jr PL et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004; 104: 1559-1564.
6. Ho VT, Zahrieh D, Hochberg E, Micale E, Levin J, Reynolds C et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 1224-1226.
7. Holler E, Kolb HJ, Moller A, Kempeni J, Liesenfeld S, Pechumer H et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990; 75: 1011-1016.
8. Or R, Kalinkovich A, Nagler A, Weisman Z, Naparstek E, Weiss L et al. Soluble tumor necrosis factor (sTNF) receptors: a possible prognostic marker for bone marrow transplantation-related complications. Cytokines Mol Ther 1996; 2: 243-250.
9. Choi SW, Kitko CL, Braun T, Weisman Z, Naparstek E, Weiss L et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 2008; 112: 1539-1542.
10. Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008; 111: 2470-2475.
11. Schots R, Kaufman L, Van Riet I, Ben Othman T, De Waele M, Van Camp B et al. Proinflammatory cytokines and their role in the development of major transplantrelated complications in the early phase after allogeneic bone marrow transplantation. Leukemia 2003; 17: 1150-1156.
12. Visentainer JE, Lieber SR, Persoli LB, Vigorito AC, Aranha FJ, de Brito Eid KA et al. Serum cytokine levels and acute graft-versus-host disease after HLA-identical hematopoietic stem cell transplantation. Exp Hematol 2003; 31: 1044-1050.
13. Liem LM, van Houwelingen HC, Goulmy E. Serum cytokine levels after HLA-identical bone marrow transplantation. Transplantation 1998; 66: 863-871.
14. Imamura M, Hashino S, Kobayashi H, Kubayashi S, Hirano S, Minagawa T et al. Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versushost disease. Bone Marrow Transplant 1994; 13: 745-751.
15. Fuji S, Kim SW, Fukuda T, Mori S, Yamasaki S, Morita-Hoshi Y et al. Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 510-517.
16. Nakamura H, Komatsu K, Ayaki M, Kawamoto S, Murakami M, Uoshima N et al. Serum levels of soluble IL-2 receptor, IL-12, IL-18, and IFN-gamma in patients with acute graft-versus-host disease after allogeneic bone marrow transplantation. J Allergy Clin Immunol 2000; 106: S45-S50.
17. Fujimori Y, Takatsuka H, Takemoto Y, Hara H, Okamura H, Nakanishi K et al. Elevated interleukin (IL)-18 levels during acute graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 2000; 109: 652-657.
18. Shaiegan M, Iravani M, Babaee GR, Ghavamzadeh A. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients. Transpl Immunol 2006; 15: 223-227.
19. Thiant S, Yakoub-Agha I, Magro L, Trauet J, Coiteux V, Jouet JP et al. Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse. Bone Marrow Transplant 2010; 45: 1546-1552.
20. Uguccioni M, Meliconi R, Nesci S, Lucarelli G, Ceska M, Gasbarrini G et al. Elevated interleukin-8 serum concentrations in beta-thalassemia and graft-versus-host disease. Blood 1993; 81: 2252-2256.
21. Okamoto T, Takatsuka H, Fujimori Y, Wada H, Iwasaki T, Kakishita E. Increased hepatocyte growth factor in serum in acute graft-versus-host disease. Bone Marrow Transplant 2001; 28: 197-200.
22. Luft T, Conzelmann M, Benner A, Rieger M, Hess M, Strohhaecker U et al. Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease. Blood 2007; 110: 4535-4542.
23. Seidel C, Ringden O, Remberger M. Increased levels of syndecan-1 in serum during acute graft-versus-host disease. Transplantation 2003; 76: 423-426.
24. Kircher B, Schumacher P, Nachbaur D. Granzymes A and B serum levels in allo-SCT. Bone Marrow Transplant 2009; 43: 787-791.
25. Chen YB, McDonough S, Hasserjian R, Chen H, Coughlin E, Illiano C et al. Expression of CD30 in patients with acute graft-vs.-host disease. Blood 2012; 120: 691-696.
26. Hubel K, Cremer B, Heuser E, von Strandmann EP, Hallek M, Hansen HP. A prospective study of serum soluble CD30 in allogeneic hematopoietic stem cell transplantation. Transpl Immunol 2010; 23: 215-219.
27. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996; 272: 60-66.
28. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301-314.
29. Sackstein R. A revision of Billingham's tenets: the central role of lymphocyte migration in acute graft-versus-host disease. Biol Blood Marrow Transplant 2006; 12: 2-8.
30. Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, Serody JS. Leukocyte migration and graft-versus-host disease. Blood 2005; 105: 4191-4199.
31. von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N Engl J Med 2000; 343: 1020-1034.
32. Chen YB, Kim HT, McDonough S, Odze RD, Yao X, Lazo-Kallanian S et al. Up-regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 1066-1076.
33. Chen YB, McDonough S, Chen H, Kennedy J, Ballen KK, Dey BR et al. Expression of a4b7 Integrin on Memory CD8\+ T-cells is Increased in Patients at Presentation of Acute Intestinal Graft-vs-Host Disease. Biol Blood Marrow Transplant 2012; 18: S221.
34. Piper KP, Horlock C, Curnow SJ, Arrazi J, Nicholls S, Mahendra P et al. CXCL10-CXCR3 interactions play an important role in the pathogenesis of acute graftversus-host disease in the skin following allogeneic stem-cell transplantation. Blood 2007; 110: 3827-3832.
35. Hori T, Naishiro Y, Sohma H, Suzuki N, Hatakeyama N, Yamamoto M et al. CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease. Blood 2008; 111: 4403-4412.
36. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23.
37. Tilg H, Vedolizumab Kaser A. A humanized mAb against the alpha4beta7 integrin for the potential treatment of ulcerative colitis and Crohn's disease. Curr Opin Investig Drugs 2010; 11: 1295-1304.
38. Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R et al. A biomarker panel for acute graft-versus-host disease. Blood 2009; 113: 273-278.
39. Paczesny S, Braun T, Vander Lugt A, Harris B, Fiema J, Hernandez J et al. A three biomarker panel at days 7 and 14 can predict development of grade II-IV acute graft-versus-host disease. Biol Blood Marrow Transplant 2011; 17: S167.
40. Paczesny S, Levine JE, Braun TM, Ferrara JL. Plasma biomarkers in graft-versushost disease: a new era? Biol Blood Marrow Transplant 2009; 15: 33-38.
41. Kaiser T, Kamal H, Rank A, Kolb HJ, Holler E, Ganser A et al. Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 340-349.
42. Weissinger EM, Schiffer E, Hertenstein B, Ferrara JL, Holler E, Stadler M et al. Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2007; 109: 5511-5519.
43. Paczesny S, Braun TM, Levine JE, Hogan J, Crawford J, Coffing B et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med 2010; 2: 13ra2.
44. Harris AC, Ferrara JL, Levine JE, Braun T, Hogan J, Crawford J et al. Reg3a is a biomarker of graft versus host disease of the gastrointestinal tract. Biol Blood Marrow Transplant 2011; 17: S163-S164.
45. Alousi AM, Weisdorf DJ, Logan BR, Bolaños-Meade J, Carter S, Difronzo N et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009; 114: 511-517.
46. Levine JE, Logan BR, Wu J, Alousi AM, Bolaños-Meade J, Ferrara JL et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood 2012; 119: 3854-3860.
47. Rodriguez-Otero P, Porcher R, Peffault de Latour R, Contreras M, Bouhnik Y, Xhaard A et al. Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastro-intestinal graft-versus-host disease. Blood 2012; 119: 5909-5917.
48. Bacigalupo A, Oneto R, Bruno B, Soracco M, Lamparelli T, Gualandi F et al. Early predictors of transplant-related mortality (TRM) after allogeneic bone marrow transplants (BMT): blood urea nitrogen (BUN) and bilirubin. Bone Marrow Transplant 1999; 24: 653-659.
49. Bacigalupo A, Oneto R, Lamparelli T, Gualandi F, Bregante S, Raiola AM et al. Preemptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG). Bone Marrow Transplant 2001; 28: 1093-1096.
50. Sormani MP, Oneto R, Bruno B, Fiorone M, Lamparelli T, Gualandi F et al. A revised day \+7 predictive score for transplant-related mortality: serum cholinesterase, total protein, blood urea nitrogen, gamma glutamyl transferase, donor type and cell dose. Bone Marrow Transplant 2003; 32: 205-211.
51. Bacigalupo A, Lamparelli T, Milone G, Sormani MP, Ciceri F, Peccatori J et al. Preemptive treatment of acute GVHD: a randomized multicenter trial of rabbit antithymocyte globulin, given on day\+7 after alternative donor transplants. Bone Marrow Transplant 2010; 45: 385-391.
52. Mohty M, Blaise D, Faucher C, Vey N, Bouabdallah R, Stoppa AM et al. Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2005; 106: 4407-4411.
53. Srinivasan R, Daniels J, Fusaro V, Lundqvist A, Killian JK, Geho D et al. Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Exp Hematol 2006; 34: 796-801.